151. Clinicopathological analysis of oral diffuse large B-cell lymphoma, NOS: A systematic review
- Author
-
Pablo Agustin Vargas, Sara Ferreira Dos Santos-Costa, Carla Isabelly Rodrigues-Fernandes, Javier Rendón Henao, Oslei Paes de Almeida, Hélder Antônio Rebelo Pontes, Felipe Paiva Fonseca, Lucas Lacerda de Souza, Peter A. Brennan, and Siavash Rahimi
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Mandible ,CHOP ,Malignancy ,Gastroenterology ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Sex Factors ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Maxilla ,Humans ,Stage (cooking) ,Survival rate ,Neoplasm Staging ,Univariate analysis ,Mouth ,business.industry ,030206 dentistry ,medicine.disease ,Prognosis ,Lymphoma ,Survival Rate ,Otorhinolaryngology ,B symptoms ,030220 oncology & carcinogenesis ,Periodontics ,Female ,Mouth Neoplasms ,Lymphoma, Large B-Cell, Diffuse ,Oral Surgery ,medicine.symptom ,business ,Diffuse large B-cell lymphoma - Abstract
Background Diffuse large B-cell lymphoma, NOS (DLBCL NOS) is the commonest extranodal non-Hodgkin lymphoma diagnosed in the oral and maxillofacial region. However, few studies are currently available and its prognostic determinants remain undefined. Purpose To analyse the available data on oral DLBCL NOS and to describe its clinicopathological features, identifying potential prognostic factors. Methods An electronic systematic search was performed using multiple databases with a specific search strategy in April 2018. All reports describing DLBCL NOS involving the oral cavity and jaw bones with sufficient clinicopathological information were assessed. Results Sixty-three publications were included in the study, comprising 122 cases. Oral DLBCL NOS was found predominantly in elderly males (61.5%), and most often presented as an asymptomatic swelling of the gingiva. Patients commonly were HIV-negative (36.1%), with few reports describing EBV-positive cases (four cases/3.3%). Only eight cases presented B symptoms and most cases were classified as stage I or II (48.4%). CHOP therapy was the main treatment option (24.5%) and the overall 5-year survival rate achieved 83%. Males and advanced Ann Arbor stage patients presented significantly lower survival rates in the univariate analysis, but no significance was found in the multivariate model. Conclusion Oral DLBCL NOS is an aggressive malignancy, but with a high survival rate.
- Published
- 2018